| __timestamp | BioMarin Pharmaceutical Inc. | Biogen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 1171036000 |
| Thursday, January 1, 2015 | 152008000 | 1240400000 |
| Friday, January 1, 2016 | 209620000 | 1478700000 |
| Sunday, January 1, 2017 | 241786000 | 1630000000 |
| Monday, January 1, 2018 | 315264000 | 1816300000 |
| Tuesday, January 1, 2019 | 359466000 | 1955400000 |
| Wednesday, January 1, 2020 | 524272000 | 1805200000 |
| Friday, January 1, 2021 | 470515000 | 2109700000 |
| Saturday, January 1, 2022 | 483669000 | 2278300000 |
| Sunday, January 1, 2023 | 577065000 | 2533400000 |
| Monday, January 1, 2024 | 580235000 | 0 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding cost structures is crucial. Over the past decade, Biogen Inc. and BioMarin Pharmaceutical Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, Biogen's cost of revenue surged by approximately 116%, peaking at $2.53 billion in 2023. In contrast, BioMarin's cost of revenue increased by about 345%, reaching $577 million in the same year. This stark difference highlights Biogen's larger scale of operations compared to BioMarin. However, BioMarin's rapid growth rate suggests a dynamic expansion strategy. These insights provide a window into the operational efficiencies and strategic priorities of these biotech giants. As the industry evolves, monitoring these financial metrics will be key to understanding their market positioning and future growth trajectories.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Biogen Inc.
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and Biogen Inc.
Cost of Revenue Comparison: Biogen Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Biogen Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.